AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval
Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.
You may also be interested in...
Thrive is developing CancerSEEK, a liquid biopsy test designed to detect cancers at earlier stages of disease.
The companies expect the Guardant360 CDx liquid-biopsy test to identify patients who will benefit from amivantamab, Janssen’s investigational drug for non-small cell lung cancer.
Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.